TGFB1 and Alzheimer disease: Accordingly, in addition to ICV administration of TGF-β1 prior to Aβ1–42 injection, IN administration of TGF-β1 after Aβ1–42 injection was also used in the present study to explore a more clinically relevant therapeutic approach for patients with AD.